{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:49:38Z","timestamp":1780584578159,"version":"3.54.1"},"reference-count":58,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI123861"],"award-info":[{"award-number":["AI123861"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI144232"],"award-info":[{"award-number":["AI144232"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009584","name":"Toyota Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100009584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013826","name":"Candys Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100013826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015459","name":"Danish Cancer Society Research Center","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100015459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008269","name":"L\u00e6ge Sophus Carl Emil Friis og hustru Olga Doris Friis' Legat","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100008269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"K\u00f8benhavns Universitet","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Region Hovedstaden","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mauritzen La Fontaine Foundation","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2022,7,13]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>A prophylactic vaccine is needed to control the HCV epidemic, with genotypes 1\u20133 causing &gt;80% of worldwide infections. Vaccine development is hampered by HCV heterogeneity, viral escape including protection of conserved neutralising epitopes and suboptimal efficacy of HCV cell culture systems. We developed cell culture-based inactivated genotype 1\u20133 HCV vaccine candidates to present natively folded envelope proteins to elicit neutralising antibodies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>High-yield genotype 1a, 2a and 3a HCV were developed by serial passage of TNcc, J6cc and DBN3acc in Huh7.5 cells and engineering of acquired mutations detected by next-generation sequencing. Neutralising epitope exposure was determined in cell-based neutralisation assays using human monoclonal antibodies AR3A and AR4A, and polyclonal antibody C211. BALB\/c mice were immunised with processed and inactivated genotype 1a, 2a or 3a viruses using AddaVax, a homologue of the licenced adjuvant MF-59. Purified mouse and patient serum IgG were assayed for neutralisation capacity; mouse IgG and immune-sera were assayed for E1\/E2 binding.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Compared with the original viruses, high-yield viruses had up to ~1000\u2009fold increased infectivity titres (peak titres: 6\u20137 log10 focus-forming units (FFU)\/mL) and up to ~2470\u2009fold increased exposure of conserved neutralising epitopes. Vaccine-induced IgG broadly neutralised genotype 1\u20136 HCV (EC50: 30\u2013193\u2009\u00b5g\/mL; mean 71\u2009\u00b5g\/mL), compared favourably with IgG from chronically infected patients, and bound genotype 1\u20133 E1\/E2; immune-sera endpoint titres reached up to 32\u2009000.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>High-yield genotype 1\u20133 HCV could be developed as basis for inactivated vaccine candidates inducing broadly neutralising antibodies in mice supporting further preclinical development.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/gutjnl-2021-326323","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T13:20:12Z","timestamp":1659446412000},"page":"560-572","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice"],"prefix":"10.1136","volume":"72","author":[{"given":"Garazi Pena","family":"Alzua","sequence":"first","affiliation":[{"name":"Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Finne","family":"Pihl","sequence":"additional","affiliation":[{"name":"Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-2840","authenticated-orcid":false,"given":"Anna","family":"Offersgaard","sequence":"additional","affiliation":[{"name":"Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Rene","family":"Duarte Hernandez","sequence":"additional","affiliation":[{"name":"Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Duan","sequence":"additional","affiliation":[{"name":"Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Feng","sequence":"additional","affiliation":[{"name":"Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2527-5751","authenticated-orcid":false,"given":"Ulrik","family":"Fahn\u00f8e","sequence":"additional","affiliation":[{"name":"Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"S\u00f8lund","sequence":"additional","affiliation":[{"name":"Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Weis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansun","family":"Law","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannick C","family":"Prentoe","sequence":"additional","affiliation":[{"name":"Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Pravsgaard","family":"Christensen","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-4806","authenticated-orcid":false,"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[{"name":"Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2805-0256","authenticated-orcid":false,"given":"Judith Margarete","family":"Gottwein","sequence":"additional","affiliation":[{"name":"Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"2025090711534588000_72.3.560.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.035"},{"key":"2025090711534588000_72.3.560.2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01315"},{"key":"2025090711534588000_72.3.560.3","unstructured":"Hepatitis C . Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c [Accessed April 29, 2022]."},{"key":"2025090711534588000_72.3.560.4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009185"},{"key":"2025090711534588000_72.3.560.5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized trial of a vaccine regimen to prevent chronic HCV infection","volume":"384","author":"Page","year":"2021","journal-title":"N Engl J Med"},{"key":"2025090711534588000_72.3.560.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.4.1294"},{"key":"2025090711534588000_72.3.560.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.084"},{"key":"2025090711534588000_72.3.560.8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059776"},{"key":"2025090711534588000_72.3.560.9","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1053\/j.gastro.2019.11.282","article-title":"Antibody responses to immunization with HCV envelope glycoproteins as a baseline for B-Cell-Based vaccine development","volume":"158","author":"Chen","year":"2020","journal-title":"Gastroenterology"},{"key":"2025090711534588000_72.3.560.10","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir511"},{"key":"2025090711534588000_72.3.560.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8"},{"key":"2025090711534588000_72.3.560.12","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2668"},{"key":"2025090711534588000_72.3.560.13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27013"},{"key":"2025090711534588000_72.3.560.14","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1172\/JCI130720","article-title":"Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance","volume":"129","author":"Kinchen","year":"2019","journal-title":"J Clin Invest"},{"key":"2025090711534588000_72.3.560.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.10.012"},{"key":"2025090711534588000_72.3.560.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.013"},{"key":"2025090711534588000_72.3.560.17","doi-asserted-by":"publisher","DOI":"10.1038\/nm1698"},{"key":"2025090711534588000_72.3.560.18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1114927109"},{"key":"2025090711534588000_72.3.560.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1822002116"},{"key":"2025090711534588000_72.3.560.20","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb5938"},{"key":"2025090711534588000_72.3.560.21","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.05.007","article-title":"Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice","volume":"145","author":"Akazawa","year":"2013","journal-title":"Gastroenterology"},{"key":"2025090711534588000_72.3.560.22","doi-asserted-by":"publisher","DOI":"10.1086\/589862"},{"key":"2025090711534588000_72.3.560.23","doi-asserted-by":"publisher","DOI":"10.1038\/nm1268"},{"key":"2025090711534588000_72.3.560.24","doi-asserted-by":"publisher","DOI":"10.1126\/science.1114016"},{"key":"2025090711534588000_72.3.560.25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22673"},{"key":"2025090711534588000_72.3.560.26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1218260109"},{"key":"2025090711534588000_72.3.560.27","article-title":"Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025090711534588000_72.3.560.28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1053\/j.gastro.2016.07.013","article-title":"Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir","volume":"151","author":"Ramirez","year":"2016","journal-title":"Gastroenterology"},{"key":"2025090711534588000_72.3.560.29","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312208"},{"key":"2025090711534588000_72.3.560.30","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01605-10"},{"key":"2025090711534588000_72.3.560.31","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00039-15"},{"key":"2025090711534588000_72.3.560.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.031"},{"key":"2025090711534588000_72.3.560.33","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30647"},{"key":"2025090711534588000_72.3.560.34","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.virol.2014.03.021","article-title":"Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6","volume":"458-459","author":"Mathiesen","year":"2014","journal-title":"Virology"},{"key":"2025090711534588000_72.3.560.35","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jhep.2021.12.026","article-title":"Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice","volume":"76","author":"Pihl","year":"2022","journal-title":"J Hepatol"},{"key":"2025090711534588000_72.3.560.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59121-0"},{"key":"2025090711534588000_72.3.560.37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/vaccines8020294","article-title":"Specific antibodies induced by immunization with hepatitis B virus-like particles carrying hepatitis C virus envelope glycoprotein 2 epitopes show differential neutralization efficiency","volume":"8","author":"Czarnota","year":"2020","journal-title":"Vaccines"},{"key":"2025090711534588000_72.3.560.38","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.15.7672-7682.2002"},{"key":"2025090711534588000_72.3.560.39","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00586-11"},{"key":"2025090711534588000_72.3.560.40","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/hep.28705","article-title":"Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity","volume":"64","author":"Prentoe","year":"2016","journal-title":"Hepatology"},{"key":"2025090711534588000_72.3.560.41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27298"},{"key":"2025090711534588000_72.3.560.42","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321190"},{"key":"2025090711534588000_72.3.560.43","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1932"},{"key":"2025090711534588000_72.3.560.44","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10020249","article-title":"High-Titer hepatitis C virus production in a scalable single-use high cell density bioreactor","volume":"10","author":"Offersgaard","year":"2022","journal-title":"Vaccines"},{"key":"2025090711534588000_72.3.560.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23276-8"},{"key":"2025090711534588000_72.3.560.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.11.003"},{"key":"2025090711534588000_72.3.560.47","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.69.7.4413-4422.1995"},{"key":"2025090711534588000_72.3.560.48","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01594-10"},{"key":"2025090711534588000_72.3.560.49","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28989"},{"key":"2025090711534588000_72.3.560.50","doi-asserted-by":"crossref","first-page":"e01403","DOI":"10.1128\/JVI.01403-18","article-title":"Antigenicity and immunogenicity of differentially glycosylated hepatitis C virus E2 envelope proteins expressed in mammalian and insect cells","volume":"93","author":"Urbanowicz","year":"2019","journal-title":"J Virol"},{"key":"2025090711534588000_72.3.560.51","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01462-16"},{"key":"2025090711534588000_72.3.560.52","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/vaccines7040204","article-title":"Effect of different adjuvants on the longevity and strength of humoral and cellular immune responses to the HCV envelope glycoproteins","volume":"7","author":"Akache","year":"2019","journal-title":"Vaccines"},{"key":"2025090711534588000_72.3.560.53","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243283"},{"key":"2025090711534588000_72.3.560.54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005996"},{"key":"2025090711534588000_72.3.560.55","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2021.10.005","article-title":"An antigenically diverse, representative panel of envelope glycoproteins for hepatitis C virus vaccine development","volume":"162","author":"Salas","year":"2022","journal-title":"Gastroenterology"},{"key":"2025090711534588000_72.3.560.56","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1128\/JVI.02141-17","article-title":"Role of the E2 hypervariable region (HVR1) in the immunogenicity of a recombinant hepatitis C virus vaccine","volume":"92","author":"Law","year":"2018","journal-title":"J Virol"},{"key":"2025090711534588000_72.3.560.57","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/vaccines9070706","article-title":"SARS-CoV-2 production in a scalable high cell density bioreactor","volume":"9","author":"Offersgaard","year":"2021","journal-title":"Vaccines"},{"key":"2025090711534588000_72.3.560.58","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMsb2109093","article-title":"Controlled Human Infection Model - Fast Track to HCV Vaccine?","volume":"385","author":"Liang","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2021-326323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T18:53:56Z","timestamp":1757271236000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2021-326323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2,7]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/gutjnl-2021-326323"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2021-326323","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]}}}